IQVIA Launches Avacare Clinical Research Network to Increase Patients’ Clinical and Research Options
February 20 2020 - 8:49AM
Business Wire
IQVIA™ (NYSE: IQV), a leader in human data science, today
announced the launch of Avacare Clinical Research Network™, a
technology-based global site network that opens opportunities for
more clinical trials at experienced clinical and research sites.
Avacare’s unique analytical tools help sites in Avacare’s network
match patients to clinical trials faster and more effectively.
“We believe combining clinical research and patient care
produces better patient outcomes, reduces cost of care, and
advances research that will benefit patients,” said Cynthia Verst,
president, Design and Delivery Innovation, Research &
Development Solutions at IQVIA. “This is another example of IQVIA’s
commitment to human data science, where our Avacare network enables
practices to efficiently match trial participants to clinical
trials, advancing medical innovation.”
Previously known as Qcare, Avacare has now expanded to include
sites in the U.S. and India, with coverage across 19 therapeutic
areas. Through existing physician relationships connected to
approximately 6.5 million patients globally, Avacare provides
innovative treatment options that drive healthcare forward.
Avacare uses innovative clinical technology with advanced
analytics to deliver artificial intelligence-powered patient
referrals and data-driven enrollment trends. By utilizing
proprietary algorithms and privacy-protected health records across
sites, Avacare precisely identifies the best patients to opt-in for
each trial and supports the investigators in engaging patients for
those trials.
To learn more about IQVIA’s Avacare Clinical Research Network,
visit www.avacare.com.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced
analytics, technology solutions and contract research services to
the life sciences industry. Formed through the merger of IMS Health
and Quintiles, IQVIA applies human data science — leveraging the
analytic rigor and clarity of data science to the ever-expanding
scope of human science — to enable companies to reimagine and
develop new approaches to clinical development and
commercialization, speed innovation and accelerate improvements in
healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers
unique and actionable insights at the intersection of large-scale
analytics, transformative technology and extensive domain
expertise, as well as execution capabilities. With approximately
67,000 employees, IQVIA conducts operations in more than 100
countries.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy-enhancing
technologies and safeguards to protect individual privacy while
generating and analyzing information on a scale that helps
healthcare stakeholders identify disease patterns and correlate
with the precise treatment path and therapy needed for better
outcomes. IQVIA’s insights and execution capabilities help biotech,
medical device and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders tap
into a deeper understanding of diseases, human behaviors and
scientific advances, in an effort to advance their path toward
cures. To learn more, visit www.iqvia.com.
Click here to subscribe to Mobile Alerts for IQVIA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200220005521/en/
Tor Constantino, IQVIA Media Relations
(tor.constantino@iqvia.com) +1.484.567.6732
Andrew Markwick, IQVIA Investor Relations
(andrew.markwick@iqvia.com) +1.973.257.7144
IQVIA (NYSE:IQV)
Historical Stock Chart
From Aug 2024 to Sep 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
From Sep 2023 to Sep 2024